BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bendell JC, Bauer TM, Lamar R, Joseph M, Penley W, Thompson DS, Spigel DR, Owera R, Lane CM, Earwood C, Burris HA 3rd. A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors. Cancer Invest 2016;34:265-70. [PMID: 27379708 DOI: 10.1080/07357907.2016.1193746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Huang M, Yang W, Zhu J, Mariño-Enríquez A, Zhu C, Chen J, Wu Y, Quan Y, Qiu H, Li X, Chai L, Fletcher JA, Ou WB. Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours. Br J Cancer 2020;122:372-81. [PMID: 31776458 DOI: 10.1038/s41416-019-0657-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Shevtsov M, Multhoff G. Therapeutic Implications of Heat Shock Proteins in Cancer. In: Asea AAA, Kaur P, editors. Chaperokine Activity of Heat Shock Proteins. Cham: Springer International Publishing; 2019. pp. 211-43. [DOI: 10.1007/978-3-030-02254-9_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Kadasi S, Yerroju R, Gaddam S, Pullanagiri N, Chary M, Pingili D, Raj S, Raghavendra NM. Discovery of N-pyridoyl-Δ2 -pyrazolines as Hsp90 inhibitors. Arch Pharm (Weinheim) 2020;353:e1900192. [PMID: 31808979 DOI: 10.1002/ardp.201900192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Marcyk PT, LeBlanc EV, Kuntz DA, Xue A, Ortiz F, Trilles R, Bengtson S, Kenney TMG, Huang DS, Robbins N, Williams NS, Krysan DJ, Privé GG, Whitesell L, Cowen LE, Brown LE. Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors: Optimization of Whole-Cell Anticryptococcal Activity and Insights into the Structural Origins of Cryptococcal Selectivity. J Med Chem 2021;64:1139-69. [PMID: 33444025 DOI: 10.1021/acs.jmedchem.0c01777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Hemming ML, Heinrich MC, Bauer S, George S. Translational insights into gastrointestinal stromal tumor and current clinical advances. Ann Oncol 2018;29:2037-45. [PMID: 30101284 DOI: 10.1093/annonc/mdy309] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
6 Park S, Park JA, Jeon JH, Lee Y. Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage. Biomol Ther (Seoul) 2019;27:423-34. [PMID: 31113013 DOI: 10.4062/biomolther.2019.051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Huang DS, LeBlanc EV, Shekhar-Guturja T, Robbins N, Krysan DJ, Pizarro J, Whitesell L, Cowen LE, Brown LE. Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors. J Med Chem 2020;63:2139-80. [PMID: 31513387 DOI: 10.1021/acs.jmedchem.9b00826] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
8 Khoshnood A. Gastrointestinal stromal tumor - A review of clinical studies. J Oncol Pharm Pract 2019;25:1473-85. [PMID: 31068088 DOI: 10.1177/1078155219846955] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Kihara T, Yuan J, Watabe T, Kitajima K, Kimura N, Ohkouchi M, Hashikura Y, Ohkubo S, Takahashi T, Hirota S. Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition. Exp Mol Pathol 2021;123:104692. [PMID: 34606780 DOI: 10.1016/j.yexmp.2021.104692] [Reference Citation Analysis]
10 Ikebe E, Shimosaki S, Hasegawa H, Iha H, Tsukamoto Y, Wang Y, Sasaki D, Imaizumi Y, Miyazaki Y, Yanagihara K, Hamaguchi I, Morishita K. TAS-116 (pimitespib), a heat shock protein 90 inhibitor, shows efficacy in preclinical models of adult T-cell leukemia. Cancer Sci 2021. [PMID: 34794206 DOI: 10.1111/cas.15204] [Reference Citation Analysis]
11 Dutta Gupta S, Pan CH. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents. International Journal of Biological Macromolecules 2020;161:1086-98. [DOI: 10.1016/j.ijbiomac.2020.06.115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Ohkubo S, Nishida T. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur J Cancer 2019;121:29-39. [PMID: 31536852 DOI: 10.1016/j.ejca.2019.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
13 Epp-Ducharme B, Dunne M, Fan L, Evans JC, Ahmed L, Bannigan P, Allen C. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro. Sci Rep 2021;11:11103. [PMID: 34045581 DOI: 10.1038/s41598-021-90585-w] [Reference Citation Analysis]
14 Bai J, Zhou G, Qiu Y, Hu Y, Liu J, Zhao J, Zhang S, Zhang J. HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells. Cancer Sci 2017;108:1177-84. [PMID: 28301080 DOI: 10.1111/cas.13238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Li L, Chen NN, You QD, Xu XL. An updated patent review of anticancer Hsp90 inhibitors (2013-present). Expert Opin Ther Pat 2021;31:67-80. [PMID: 32990109 DOI: 10.1080/13543776.2021.1829595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Shen CH, Hsieh CC, Jiang KY, Lin CY, Chiang NJ, Li TW, Yen CT, Chen WJ, Hwang DY, Chen LT. AUY922 induces retinal toxicity through attenuating TRPM1. J Biomed Sci 2021;28:55. [PMID: 34301262 DOI: 10.1186/s12929-021-00751-5] [Reference Citation Analysis]
17 Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P. New targets and therapies for gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2017;17:1117-29. [PMID: 29110548 DOI: 10.1080/14737140.2017.1400386] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
18 van Willigenburg H, de Keizer PLJ, de Bruin RWF. Cellular senescence as a therapeutic target to improve renal transplantation outcome. Pharmacol Res 2018;130:322-30. [PMID: 29471104 DOI: 10.1016/j.phrs.2018.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
19 Mouratidis PXE, Ter Haar G. HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells. Int J Hyperthermia 2021;38:1443-56. [PMID: 34612127 DOI: 10.1080/02656736.2021.1983036] [Reference Citation Analysis]
20 Moon HJ, Kim HB, Lee SH, Jeun SE, Kang CD, Kim SH. Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death. Oncotarget 2018;9:11303-21. [PMID: 29541415 DOI: 10.18632/oncotarget.24130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
21 Nishida T, Yoshinaga S, Takahashi T, Naito Y. Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors. Cancers (Basel) 2021;13:3158. [PMID: 34202544 DOI: 10.3390/cancers13133158] [Reference Citation Analysis]